Velazco-Cruz Leonardo, Goedegebuure Madeleine M, Millman Jeffrey R
Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St. Louis, MO, United States.
Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO, United States.
Front Bioeng Biotechnol. 2020 Jul 9;8:786. doi: 10.3389/fbioe.2020.00786. eCollection 2020.
Human stem cell-derived β (SC-β) cells have the potential to revolutionize diabetes treatment through disease modeling, drug screening, and cellular therapy. SC-β cells are likely to represent an early clinical translation of differentiated human pluripotent stem cells (hPSC). In 2014, two groups generated the first -differentiated glucose-responsive SC-β cells, but their functional maturation at the time was low. This review will discuss recent advances in the engineering of SC-β cells to understand and improve SC-β cell differentiation and functional maturation, particularly new differentiation strategies achieving dynamic glucose-responsive insulin secretion with rapid correction to normoglycemia when transplanted into diabetic mice.
人干细胞衍生的β（SC-β）细胞有潜力通过疾病建模、药物筛选和细胞疗法彻底改变糖尿病治疗。SC-β细胞可能代表了分化的人多能干细胞（hPSC）的早期临床转化。2014年，两个研究小组首次生成了分化的葡萄糖反应性SC-β细胞，但当时它们的功能成熟度较低。本综述将讨论SC-β细胞工程的最新进展，以了解和改善SC-β细胞的分化和功能成熟，特别是新的分化策略，这些策略能实现动态葡萄糖反应性胰岛素分泌，并在移植到糖尿病小鼠体内时能迅速恢复正常血糖。
